The CEO of Jasper Therapeutics on c-KIT inhibition
- blonca9
- Apr 22, 2024
- 1 min read
Ronald Martell describes Jasper's subcu programs for urticaria and how the company also continues to test its antibody as an alternative to harsh chemotherapy preconditioning during stem cell transplants.